Risk in Devel Long-COVID in Contracting SARS-CoV-2 Infection After COVID-19 Vaccination in Relation to Vitamin D3 Suppl

Retrospective Observational Study on the Risk Developing Long-COVID Syndrome After Acute COVID-19 Disease and in Contracting SARS-CoV-2 Infection After COVID-19 Vaccination in Relation to Vitamin D3 Suppl in Outpatients of Endocr Dept

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06452082

Acronym

LONGVITAVAX2

Enrollment

200

Registered

2024-06-11

Start date

2024-03-20

Completion date

2025-09-10

Last updated

2026-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, Long COVID, Vitamin d Deficiency

Brief summary

The aim of this observational retrospective study is to evaluate the effect of supplementation with cholecalciferol D3 in reducing the risk of: * occurence of Long COVID syndrome after acute COVID-19 illness * occurence of SARS-CoV-2 infection after anti-COVID-19 vaccination

Detailed description

Anamnestic, laboratory and therapeutic data will be collected during outpatient visits.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

(For aim I): * age ≥18 * outpatient with first visit on Endocrinology Department performed from 01/01/2020 to 31/12/2022 * previous SARS CoV-2 infection * clinical,anamnestic and therapeutic data 6 months post SARS CoV-2 infection * data on cholecalciferol supplementation * signature of informed consent

Exclusion criteria

(For aim I): * age ≤ 18 * pregnant or breastfeeding women * patients suffering from primary and/or acquired immunodeficiency and/or severe impairment of general clinical conditions * patients treated with drugs that interfere with vitamin D metabolism * first vaccination anti Sars COVID performed before the acute infection * first vaccination performed within 6 months of the acute infection * patients unable to sign the informed consent Inclusion Criteria (For aim 2) \-- age ≥18 * outpatient with first visit on Endocrinology Department performed from 01/01/2020 to 31/12/2022 * vaccination with BNT162b2 Biontec mRNA Pfizer/BioNtech * clinical, anamnestic and therapeutic data 6 months post SARS CoV-2 infection * data on cholecalciferol supplementation * signature of informed consent

Design outcomes

Primary

Measure	Time frame	Description
Analyse the rates of Long COVID syndrome occurance after acute COVID-19 disease in patients treated with and without cholecalciferol.	to 01/01/2020 from 31/12/2022	Analyse the rates of Long COVID syndrome occurance after acute COVID-19 disease in outpatients treated with and without cholecalciferol between 01/01/2020 and 31/12/2022
Analyse the rates of SARS-CoV-2 infection occurrence after anti-COVID-19 vaccination in patients treated with and without cholecalciferol.	to 01/01/2020 from 31/12/2022	Analyse the rates of SARS-CoV-2 infection occurrence after anti-COVID-19 vaccination in oupatients treated with and without cholecalciferol between 01/01/2020 and 31/12/2022

Countries

Italy

Outcome results